2Q EARNINGS: Amgen cutting up to 2,900 jobs to reinvest in pipeline
This article was originally published in Scrip
Executive Summary
Amgen's second quarter sales and earnings significantly beat market consensus expectations, but the financial report was overshadowed by news that the company will cut 2,400 to 2,900 jobs and reinvest the money saved into products that may be approved in 2015.
You may also be interested in...
Amgen's Elliott Levy On Adaptive Design And Real-World Evidence Strategies
Levy, SVP of global development, notes that two years after launching an in-house Center for Design and Analysis, Amgen considers adaptive designs for most new studies and more than half include adaptive elements.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.